Unknown

Dataset Information

0

The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.


ABSTRACT: Objective: Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers. Methods: After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and estimated hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) using a fixed-effect model. Results: Our results indicate that pretreatment plasma fibrinogen is a prognostic factor in urological cancers (OS: HR=2.21, 95% CI=1.91-2.57, P<0.001, CSS: HR=2.67, 95% CI=2.23-3.19, P<0.001). Elevated pretreatment plasma fibrinogen is associated with poorer survival in prostate cancer (OS: HR=2.26, 95% CI=1.47-3.48, P<0.001; CSS: HR=2.42, 95% CI=1.44-4.07, P=0.001), renal cell carcinoma (OS: HR=2.13, 95% CI=1.75-2.61, P<0.001; CSS: HR=2.99, 95% CI=2.29-3.89, P<0.001) and upper tract urothelial carcinoma (OS: HR=2.34, 95% CI=1.81-3.02, P<0.001; CSS: HR=2.43, 95% CI=1.84-3.20, P<0.001). Subgroup analyses showed that plasma fibrinogen has a more negative impact on survival in Caucasian patients (OS: HR=2.52, 95% CI=1.95-3.25, P<0.001; CSS: HR=2.83, 95% CI=1.92-4.17, P<0.001) than Asian patients (OS: HR=2.07, 95% CI=1.73-2.49, P<0.001; CSS: HR=2.63, 95% CI=2.14-3.22, P<0.001). The prognostic value of fibrinogen is also consistent when stratified by different cut-off values. Conclusions: These results show that high pretreatment plasma fibrinogen levels can predict poorer OS and CSS in patients with urological cancers.

SUBMITTER: Song H 

PROVIDER: S-EPMC6360290 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.

Song Haifeng H   Kuang Guanyu G   Zhang Zhenan Z   Ma Binglei B   Jin Jie J   Zhang Qian Q  

Journal of Cancer 20190101 2


<b><i>Objective:</i></b> Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers. <b><i>Methods:</i></b> After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and es  ...[more]

Similar Datasets

| S-EPMC5684392 | biostudies-literature
| S-EPMC5362543 | biostudies-literature
| S-EPMC7171794 | biostudies-literature
| S-EPMC5707108 | biostudies-literature
| S-EPMC5522151 | biostudies-literature
| S-EPMC5754056 | biostudies-literature
| S-EPMC4668575 | biostudies-literature
| S-EPMC7887688 | biostudies-literature
| S-EPMC7683770 | biostudies-literature
| S-EPMC7178593 | biostudies-literature